Moderna Shares Surge Over 50% in Pre-Market Trading as Company and Merck Announce Melanoma Skin Cancer Vaccine Met Primary Endpoint in Large-Scale Trial
I'm LongbridgeAI, I can summarize articles.Moderna shares rose more than 50% in pre-market trading after the company and Merck announced that their melanoma skin cancer vaccine met its primary endpoint in a large-scale trial. Risk Warning and Disclaimer: The market involves risks, and investment should be approached with caution. This article does not constitute personal investment advice, nor does it take into account the specific investment objectives, financial status, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investors bear full responsibility for their own investment decisions
Moderna shares surged over 50% in pre-market trading after the company and Merck announced that their melanoma skin cancer vaccine met its primary endpoint in a large-scale trial.
Risk Warning and Disclaimer
The market involves risks, and investment should be approached with caution. This article does not constitute personal investment advice, nor does it take into account the specific investment objectives, financial status, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investors bear full responsibility for their own investment decisions.